| scholarly article | Q13442814 |
| P2093 | author name string | D Brömme | |
| M G Barnes | |||
| M E McGrath | |||
| J L Klaus | |||
| P2860 | cites work | Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment | Q24561952 |
| The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity | Q27651464 | ||
| Structure of papain refined at 1.65 A resolution | Q27729147 | ||
| Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors | Q27730182 | ||
| Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion | Q27733264 | ||
| Binding of chloromethyl ketone substrate analogues to crystalline papain | Q27749019 | ||
| The Protein Data Bank: a computer-based archival file for macromolecular structures | Q27860989 | ||
| Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification | Q28280533 | ||
| Assessment of protein models with three-dimensional profiles | Q28283805 | ||
| Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency | Q28284581 | ||
| Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution | Q28290432 | ||
| Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping | Q28296680 | ||
| The gene for pycnodysostosis maps to human chromosome 1cen–q21 | Q28296690 | ||
| Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. | Q30321506 | ||
| Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts | Q36800896 | ||
| An unequivocal example of cysteine proteinase activity affected by multiple electrostatic interactions | Q38303889 | ||
| Effects of the proteinase inhibitors leupeptin and E-64 on osteoclastic bone resorption | Q41391057 | ||
| The electrostatic fields in the active-site clefts of actinidin and papain | Q41808250 | ||
| Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme | Q42064898 | ||
| The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts | Q42200186 | ||
| Mercaptide-imidazolium ion-pair: the reactive nucleophile in papain catalysis | Q43480902 | ||
| The active site of papain. All-atom study of interactions with protein matrix and solvent | Q43761495 | ||
| Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors | Q46097132 | ||
| The crystal structure of cruzain: a therapeutic target for Chagas' disease | Q46209844 | ||
| Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. | Q55065488 | ||
| Alignment/phylogeny of the papain superfamily of cysteine proteases. | Q64912832 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | crystal structure | Q895901 |
| P304 | page(s) | 105-9 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Nature structural biology | Q26842658 |
| P1476 | title | Crystal structure of human cathepsin K complexed with a potent inhibitor | |
| P478 | volume | 4 |
| Q44461812 | 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity |
| Q35683586 | 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents |
| Q57845086 | A Human RNA Viral Cysteine Proteinase That Depends upon a Unique Zn2+-binding Finger Connecting the Two Domains of a Papain-like Fold |
| Q27627151 | A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease |
| Q55645981 | Advances in the discovery of cathepsin K inhibitors on bone resorption. |
| Q44601532 | An assessment of protein–ligand binding site polarizability |
| Q58039002 | Binding modes of a new epoxysuccinyl–peptide inhibitor of cysteine proteases. Where and how do cysteine proteases express their selectivity? |
| Q33843319 | Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. |
| Q34523628 | Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate |
| Q44935351 | Comprehensive search for cysteine cathepsins in the human genome |
| Q34137760 | Congopain from Trypanosoma congolense: drug target and vaccine candidate. |
| Q42846520 | Crystal structure of human cathepsin S. |
| Q27748903 | Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function |
| Q27617382 | Crystal structure of wild-type human procathepsin K |
| Q26860406 | Cysteine cathepsins: from structure, function and regulation to new frontiers |
| Q74151522 | Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B |
| Q92942733 | Effective Estimation of Ligand-Binding Affinity Using Biased Sampling Method |
| Q55407794 | Evaluation of variability in high-resolution protein structures by global distance scoring. |
| Q74127761 | Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells |
| Q35108627 | Functional analysis of C1 family cysteine peptidases in the larval gut of Тenebrio molitor and Tribolium castaneum |
| Q41703462 | Functional genomics: going forwards from the databases |
| Q36420004 | Functional site profiling and electrostatic analysis of cysteines modifiable to cysteine sulfenic acid. |
| Q33533831 | Genomics and the discovery of new drug targets |
| Q22008028 | Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization |
| Q40625059 | Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor |
| Q37933395 | Inhibitors of cathepsin K: a patent review (2004 - 2010). |
| Q46686104 | Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation. |
| Q36724874 | Interstitial collagen catabolism |
| Q92123737 | Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors |
| Q26749121 | Lysosomal cathepsins and their regulation in aging and neurodegeneration |
| Q44068250 | Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer |
| Q33857460 | Lysosomal cysteine proteases: more than scavengers |
| Q42611608 | Molecular and enzymatic properties of a cathepsin L-like proteinase with distinct substrate specificity from northern shrimp (Pandalus borealis). |
| Q42020009 | Molecular cloning of a multidomain cysteine protease and protease inhibitor precursor gene from the tobacco hornworm (Manduca sexta) and functional expression of the cathepsin F-like cysteine protease domain |
| Q36915183 | Molecular dynamics simulations of the catalytic pathway of a cysteine protease: a combined QM/MM study of human cathepsin K. |
| Q33553302 | Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation |
| Q33638719 | Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L and B. |
| Q77068004 | Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors |
| Q52591302 | Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability. |
| Q44736425 | Ovarian cysteine proteinases in the teleost Fundulus heteroclitus: molecular cloning and gene expression during vitellogenesis and oocyte maturation |
| Q42169600 | Papain-like cysteine proteases |
| Q40843326 | Peptidomimetic design |
| Q33893283 | Phylogenetic relationships and theoretical model of human cathepsin W (lymphopain), a cysteine proteinase from cytotoxic T lymphocytes. |
| Q44105379 | Preparation of active recombinant cathepsin K expressed in bacteria as inclusion body |
| Q41710645 | Proregion structure of members of the papain superfamily. Mode of inhibition of enzymatic activity |
| Q28612038 | Proteolysis and antigen presentation by MHC class II molecules |
| Q98389656 | SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells |
| Q34708862 | Structural basis of collagen fiber degradation by cathepsin K. |
| Q73077056 | Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo |
| Q78181645 | Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids |
| Q47842705 | Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors |
| Q40749083 | Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics |
| Q43588615 | Subsite specificity of trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids |
| Q27635416 | Tetrameric dipeptidyl peptidase I directs substrate specificity by use of the residual pro-part domain |
| Q56762869 | The Impact of Genomics on Drug Discovery |
| Q36281760 | The N-terminal region of cystatin A (stefin A) binds to papain subsequent to the two hairpin loops of the inhibitor. Demonstration of two-step binding by rapid-kinetic studies of cystatin A labeled at the N-terminus with a fluorescent reporter group |
| Q36572175 | The consequences of lysosomotropism on the design of selective cathepsin K inhibitors |
| Q27639638 | The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators |
| Q32053006 | The new partnership of genomics and chemistry for accelerated drug development |
| Q27656389 | Toxoplasma gondii Cathepsin L Is the Primary Target of the Invasion-inhibitory Compound Morpholinurea-leucyl-homophenyl-vinyl Sulfone Phenyl |
| Q27672483 | Turnover-Dependent Covalent Inactivation of Staphylococcus aureus Coenzyme A-Disulfide Reductase by Coenzyme A-Mimetics: Mechanistic and Structural Insights |
Search more.